SHANG.FOS.PHARM.GR.H YC 1 Net Assets
SHANG.FOS.PHARM.GR.H YC 1 net assets. Based on the latest financial reports, SHANG.FOS.PHARM.GR.H YC 1 (08HH) has net assets worth €63.67 Billion EUR (≈ $74.44 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€122.97 Billion ≈ $143.76 Billion USD) and total liabilities (€59.30 Billion ≈ $69.32 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore 08HH shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €63.67 Billion |
| % of Total Assets | 51.78% |
| Annual Growth Rate | 6.33% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 3.29 |
Net Assets of SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
Net assets of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025. This chart illustrates how SHANG.FOS.PHARM.GR.H YC 1's net assets have evolved over time, based on quarterly financial data. See SHANG.FOS.PHARM.GR.H YC 1 balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for SHANG.FOS.PHARM.GR.H YC 1 (2021–2025)
The table below shows the annual net assets of SHANG.FOS.PHARM.GR.H YC 1 from 2021 to 2025. For live market cap and overall valuation, see SHANG.FOS.PHARM.GR.H YC 1 market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €61.84 Billion ≈ $72.30 Billion |
+3.18% |
| 2024-12-31 | €59.93 Billion ≈ $70.07 Billion |
+5.86% |
| 2023-12-31 | €56.62 Billion ≈ $66.19 Billion |
+4.63% |
| 2022-12-31 | €54.11 Billion ≈ $63.26 Billion |
+11.84% |
| 2021-12-31 | €48.38 Billion ≈ $56.56 Billion |
-- |
Equity Component Analysis
This analysis shows how different components contribute to SHANG.FOS.PHARM.GR.H YC 1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 38.2% over the analyzed period, indicating profitable operations and earnings retention.
SHANG.FOS.PHARM.GR.H YC 1 Net Assets Breakdown (December 2025)
SHANG.FOS.PHARM.GR.H YC 1 net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €29.06 Billion | 59.62% |
| Other Components | €19.68 Billion | 40.38% |
| Total Equity | €48.74 Billion | 100.00% |
SHANG.FOS.PHARM.GR.H YC 1 Competitors by Market Cap
The table below lists competitors of SHANG.FOS.PHARM.GR.H YC 1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Rapport Therapeutics, Inc. Common Stock
NASDAQ:RAPP
|
$1.20 Billion |
|
MIPS AB
ST:MIPS
|
$1.20 Billion |
|
Bangkok Life Assurance Public Company Limited
BK:BLA
|
$1.20 Billion |
|
British American Tobacco PLC
LSE:BATS
|
$1.20 Billion |
|
NAVIGATOR HLDGS LTD
F:1NV
|
$1.20 Billion |
|
Mitra Adiperkasa Tbk
JK:MAPI
|
$1.20 Billion |
|
VIEL & Cie société anonyme
PA:VIL
|
$1.20 Billion |
|
Porch Group Inc
NASDAQ:PRCH
|
$1.20 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SHANG.FOS.PHARM.GR.H YC 1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 47,261,106,861 to 48,741,507,005, a change of 1,480,400,144 (3.1%).
- Net income of 3,370,561,563 contributed positively to equity growth.
- Dividend payments of 1,944,642,561 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €3.37 Billion | +6.92% |
| Dividends Paid | €1.94 Billion | -3.99% |
| Other Changes | €54.48 Million | +0.11% |
| Total Change | €- | 3.13% |
Book Value vs Market Value Analysis
This analysis compares SHANG.FOS.PHARM.GR.H YC 1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.10x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €15.29 | €1.86 | x |
| 2022-12-31 | €16.68 | €1.86 | x |
| 2023-12-31 | €17.10 | €1.86 | x |
| 2024-12-31 | €17.69 | €1.86 | x |
| 2025-12-31 | €18.25 | €1.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SHANG.FOS.PHARM.GR.H YC 1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 6.92%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 8.09%
- • Asset Turnover: 0.35x
- • Equity Multiplier: 2.46x
- Recent ROE (6.92%) is below the historical average (7.69%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | 12.06% | 12.12% | 0.42x | 2.38x | €809.15 Million |
| 2022 | 8.37% | 8.49% | 0.41x | 2.40x | €-727.44 Million |
| 2023 | 5.22% | 5.76% | 0.36x | 2.48x | €-2.18 Billion |
| 2024 | 5.86% | 6.74% | 0.35x | 2.49x | €-1.96 Billion |
| 2025 | 6.92% | 8.09% | 0.35x | 2.46x | €-1.50 Billion |
Industry Comparison
This section compares SHANG.FOS.PHARM.GR.H YC 1's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,520,186,793
- Average return on equity (ROE) among peers: -111.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SHANG.FOS.PHARM.GR.H YC 1 (08HH) | €63.67 Billion | 12.06% | 0.93x | $1.20 Billion |
| PEPTONIC MEDICAL (28L) | $47.09 Million | -78.27% | 0.82x | $5.52 Million |
| Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (2TZ) | $5.05 Billion | 11.11% | 0.41x | $692.11 Million |
| WEST ISLAND BRANDS INC. (39N0) | $3.27 Million | -157.21% | 0.88x | $1.34 Million |
| HANSOH PHARMAC. HD-00001 (3KY) | $35.36 Billion | 15.71% | 0.13x | $22.06 Billion |
| AYURCANN HOLDINGS CORP. (3ZQ0) | $534.88K | -741.80% | 26.77x | $97.35K |
| CERENO SCIENTIFIC AB B (4A1) | $201.51 Million | -13.72% | 0.07x | $60.94 Million |
| MAPLE LEAF GREEN WORLD (4HV0) | $-8.83 Million | 0.00% | 0.00x | $504.30K |
| LORDS CO. WORLDW. HOLD. (4XM) | $-1.01 Million | 0.00% | 0.00x | $134.78K |
| RED LIGHT HOLLAND CORP. (4YX) | $20.26 Million | -37.64% | 0.19x | $6.62 Million |
About SHANG.FOS.PHARM.GR.H YC 1
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. engages in the pharmaceutical business in Mainland China and internationally. It operates through five segments: Pharmaceuticals, Medical Devices and Medical Diagnosis, Medical Services, Medical Distribution and Retail, and Others. The company is involved in the pharmaceutical manufacturing in the therapeutic areas of solid oncology, including tumor… Read more